Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc., filed a Form 4 on November 20, 2026, disclosing stock option exercises and a same-day sale of common stock that took place on November 18, 2026, under a Rule 10b5-1 trading plan.
Key Highlights
- Four option lots exercised: Shulman exercised options covering 1,961 shares at $6.80, 4,188 shares at $27.35, 24,944 shares at $49.23, and 9,374 shares at $56.69, all on November 18, 2026.
- 45,921 shares sold: All 45,921 shares acquired through the exercises were disposed of on November 18, 2026, at a weighted average price of $119.9049 per share, in multiple transactions ranging from $119.75 to $120.36.
- Remaining direct ownership: Following all reported transactions, Shulman directly held 10,461 shares of common stock, according to the filing.
- 10b5-1 plan: The exercises and sale were effected pursuant to a Rule 10b5-1 trading plan the reporting person adopted on December 15, 2025.
- Remaining options: After the exercises, Shulman retained 3,984, 8,375, 25,306, and 28,126 options under the four respective grants, the filing disclosed.
Shulman's November 18 Option Exercises and Share Sale at Rhythm Pharmaceuticals
According to the Form 4 filed with the SEC on November 20, 2026, Joseph Shulman, Chief Technical Officer at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), exercised four separate tranches of stock options on November 18, 2026. The option lots carried exercise prices of $6.80, $27.35, $49.23, and $56.69, covering 1,961, 4,188, 24,944, and 9,374 shares, respectively. Each lot was acquired with a transaction code of "M," indicating an exercise of derivative securities.
On the same date, Shulman disposed of 45,921 shares of common stock at a weighted average price of $119.9049. The filing noted that the securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per share, and that full information on the number of shares sold at each separate price is available upon request to the issuer, any security holder, or SEC staff. Following these transactions, Shulman's direct beneficial ownership stood at 10,461 shares of common stock.
The filing disclosed that all four option grants vest and become exercisable in 16 substantially equal installments upon completion of each three full months of successive service following the respective grant dates: February 9, 2022; February 1, 2023; February 16, 2024; and February 14, 2025. The transactions were carried out pursuant to a Rule 10b5-1 trading plan adopted by Shulman on December 15, 2025. The Form 4 was signed by Stephen Vander Stoep as attorney-in-fact for Joseph Shulman.
What Was Disclosed
The filing reported the exercise of four stock option lots totaling 40,467 shares and the sale of 45,921 shares of Rhythm Pharmaceuticals common stock by Chief Technical Officer Joseph Shulman on November 18, 2026, under a pre-established 10b5-1 trading plan.





Please wait processing your request...